Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show

Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168 for the Treatment of ALS at Neuroscience 2021 Annual Meeting

Tranquis Therapeutics, a private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases by reprogramming dysfunctional myeloid immune cells, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN). This meeting is being held virtually November 8-11, 2021, with Preview Days taking place November 3-7. The data illustrate the potential of TQS-168 for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed increased median survival and decreased pro-inflammatory cytokines and inflammatory monocytes in a widely used SOD1-G93A transgenic mouse model and demonstrated a similar decrease in inflammatory monocytes in blood from ALS patients.

"These data provide convincing evidence that validates our unique approach of developing first-in-class therapeutics that target immune mediated CNS and non-CNS indications by reprogramming dysfunctional myeloid cells, and that our lead program has the potential to become a disease-modifying therapy that would benefit ALS patients," said Jonas Hannestad, MD, PhD, Chief Medical Officer and Head of R&D at Tranquis. "We believe TQS-168 represents a new class of treatment for ALS patients and these data paint a compelling picture which shows, in this preclinical model, a potential advance over approved treatments such as riluzole and edaravone. Based on these findings, we are rapidly advancing TQS-168 into Phase1 clinical studies to assess safety, pharmacokinetics, and pharmacodynamics."

While the pathogenesis of ALS is not fully understood, it's known that inflammation, including activation of myeloid cells, plays a key role and that pro-inflammatory cytokines and monocytes are hallmarks of disease progression.

Poster Presentation Details
Title: The small molecule myeloid cell modulator TQS-168 normalizes the inflammatory phenotype of immune cells from ALS patients and extends survival in the SOD1-G93A ALS mouse model
Presenter: Hope Lancero, Ph.D., Scientist, Tranquis Therapeutics
Date/Time: Tuesday Nov. 9, 2021 at 9:45 AM CT
Poster number: 2021-S-7606-SfN
Session: P230

Key Conclusions:
The effects of TQS-168 were evaluated in vivo in a SOD1-G93A murine model of ALS and ex vivo in blood samples from ALS patients. A 50-mg/kg dose of TQS-168 was administered three times per week in the SOD1-G93A murine model. Blood samples from patients with ALS were incubated for 4 hours at various concentrations of TQS-168.

About Tranquis

Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming dysfunctional myeloid immune cells to revolutionize the management of a broad range of mitochondrial and immune mediated CNS and non-CNS indications and to significantly improve the lives of millions of patients. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis' novel therapies work by restoring normal mitochondrial biogenesis, cell homeostasis and function, effectively "switching" microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism. For more information, visit www.tranquis.com.

These press releases may also interest you

at 03:00
Steve Jobs had it. Martha Stewart has it. So do many athletes and workaholics...an obsession with being perfect. Extreme perfectionists are not just pedantic or doggedly determined to do their best, they are absolutely terrified of being seen as a...

at 01:50
Global innovation platform, Plug and Play Japan KK (Japan office: Shibuya-ku, Tokyo, Representative: Phillip Vincent, Hereinafter "Plug and Play Japan") has selected 74 startups from Japan and overseas for the Winter/Spring 2023 Batch accelerator...

2 déc 2022
Bark Technologies announced a multi-year MVNO agreement with T-Mobile for T-Mobile to serve as the exclusive nationwide network for the online safety leader's newest product launch ? the all-in-one Bark Phone. The MVNO agreement will provide...

2 déc 2022
Yiren Digital Ltd. ("Yiren Digital" or the "Company") , a leading digital personal financial management platform in China, today announced that it has received a letter dated December 1, 2022 from the New York Stock Exchange (the "NYSE") informing...

2 déc 2022
Today Stinger Off-Road, leading designer and manufacturer of aftermarket technology for Wrangler and Truck owners, released its ultimate gift guide for the Jeep Wrangler JK owner on your holiday list....

2 déc 2022
AUO Display Plus (ADP) will participate in the...

News published on 3 november 2021 at 12:10 and distributed by: